Correlation between quantitative HER-2 protein expression and risk for brain metastases in HER-2+ advanced breast cancer patients receiving trastuzumab-containing therapy

Oncologist

Volumn 17, Issue 1, 2012, Pages 26-35

  Duchnowska, Renata ^a,m   Biernat, Mwojciech ^b,m   Szostakiewicz, Barbara ^b,m   Sperinde, Jeff ^c   Piette, Fanny ^d   Haddad, Mojgan ^c   Paquet, Agnes ^c   Lie, Yolanda ^c   Czartoryska Arlukowicz, Bogumila ^e,m   Wysocki, Piotr ^f,m   Jankowski, Tomasz ^g   Radecka, Barbara ^h   Foszczyńska Kloda, Malgorzata ^i,m   Litwiniuk, Maria ^j,m   Debska, Sylwia ^k,m   Weidler, Jodi ^c   Huang, Weidong ^c   Buyse, Marc ^d   Bates, Michael ^l   Jassem, Jacek ^b,m  

^a MILITARY INSTITUTE OF MEDICINE   (Poland)

^b MEDICAL UNIVERSITY OF GDANSK   (Poland)

^c MONOGRAM BIOSCIENCES   (United States)

^d INTERNATIONAL DRUG DEVELOPMENT INSTITUTE   (Belgium)

^e Department of Radiotherapy II   (Poland)

^f Greatpoland Cancer Center   (Poland)

^g Lublin Oncology Center   (Poland)

^h Opole Oncology Center   (Poland)

ⁱ Westpomeranian Oncology Centre   (Poland)

^j POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^k Regional Cancer Center   (Poland)

^l Oncology Research and Development   (United States)

^m Polish Brain Metastasis Consortium ^*  (Poland)

more..

Author keywords

Advanced breast cancer; Brain metastasis; HER 2 amplification; Quantitative HER 2 protein level; Trastuzumab

Indexed keywords

CAPECITABINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; NAVELBINE; PROGESTERONE RECEPTOR; TAXANE DERIVATIVE; TRASTUZUMAB;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BRAIN METASTASIS; BREAST CANCER; CANCER GRADING; CORRELATION ANALYSIS; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; MAJOR CLINICAL STUDY; MEDICAL HISTORY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RELAPSE; RETROSPECTIVE STUDY; RISK FACTOR;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; BREAST NEOPLASMS; FEMALE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MIDDLE AGED; NEOPLASM METASTASIS; RECEPTOR, ERBB-2; RISK FACTORS;

EID: 84863030744     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2011-0212     Document Type: Article

References (46)

1. Tsukada Y, Fouad A, Pickren JW et al. Central nervous system metastasis from breast carcinoma. Autopsy study. Cancer 1983;52:2349-2354.
2. Schouten LJ, Rutten J, Huveneers HA et al. Incidence of brain metastases in a cohort of patients with carcinoma of the breast, colon, kidney, and lung and melanoma. Cancer 2002;94:2698-2705.
3. Hicks DG, Short SM, Prescott NL et al. Breast cancers with brain metastases are more likely to be estrogen receptor negative, express the basal cytokeratin CK5/6, and overexpress HER2 or EGFR. Am J Surg Pathol 2006;30:1097-1104.
4. Gabos Z, Sinha R, Hanson J et al. Prognostic significance of human epidermal growth factor receptor positivity for the development of brain metastasis after newly diagnosed breast cancer. J Clin Oncol 2006;24:5658-5663.
5. Gonzalez-Angulo AM, Cristofanilli M, Strom EA et al. Central nervous system metastases in patients with high-risk breast carcinoma after multimodality treatment. Cancer 2004;101:1760-1766.
6. Smid M, Wang Y, Zhang Y et al. Subtypes of breast cancer show preferential site of relapse. Cancer Res 2008;68:3108-3114.
7. Bos PD, Zhang XH, Nadal C et al. Genes that mediate breast cancer metastasis to the brain. Nature 2009;459:1005-1009.
8. Nguyen DX, Bos PD, Massagué J. Metastasis: From dissemination to organ-specific colonization. Nat Rev Cancer 2009;9:274-284.
9. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. NEngl J Med 2001;344:783-792.
10. Burstein HJ, Keshaviah A, Baron AD et al. Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: The trastuzumab and vinorelbine or taxane study. Cancer 2007;110:965-972.
11. Marty M, Cognetti F, MaraninchiDet al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: The M77001 Study Group. J Clin Oncol 2005;23:4265-4274.
12. Schaller G, Fuchs I, Gonsch T et al. Phase II study of capecitabine plus trastuzumab in human epidermal growth factor receptor 2 overexpressing metastatic breast cancer pretreated with anthracyclines or taxanes. J Clin Oncol 2007;25:3246-3250.
13. Robert N, Leyland-Jones B, Asmar L et al. Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 2006;24: 2786-2792.
14. Pestalozzi BC, Brignoli S. Trastuzumab in CSF. J Clin Oncol 2000;18:2349-2351.
15. Stemmler HJ, Schmitt M, Willems A et al. Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood-brain barrier. Anticancer Drugs 2007;18:23-28.
16. Bendell JC, Domchek SM, Burstein HJ et al. Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer 2003;97:2972-2977.
17. Shmueli E, Wigler N, Inbar M. Central nervous system progression among patients with metastatic breast cancer responding to trastuzumab treatment. Eur J Cancer 2004;40:379-382.
18. Clayton AJ, Danson S, Jolly S et al. Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer. Br J Cancer 2004;91:639-643.
19. Lai R, Dang CT, Malkin MG et al. The risk of central nervous system metastases after trastuzumab therapy in patients with breast carcinoma. Cancer 2004;101:810-816.
20. Lower EE, Drosick RD, Blau R et al. Increased rate of brain metastases with trastuzumab therapy not associated with impaired survival. Clin Breast Cancer 2003;4:114-119.
21. Burstein HJ, Lieberman G, Slamon DJ et al. Isolated central nervous system metastases in patients with HER2-overexpressing advanced breast cancer treated with first-line trastuzumab-based therapy. Ann Oncol 2005;16:1772-1777.
22. Stemmler HJ, Kahlert S, Siekiera W et al. Characteristics of patients with brain metastases receiving trastuzumab for HER2 overexpressing metastatic breast cancer. Breast 2006;15:219-225.
23. Gori S, Rimondini S, De Angelis V et al. Central nervous system metastases in HER-2 positive metastatic breast cancer patients treated with trastuzumab: Incidence, survival, and risk factors. The Oncologist 2007;12:766-773.
24. Duchnowska R, Dziadziuszko R, Czartoryska-Arłukowicz B et al. Risk factors for brain relapse in HER2-positive metastatic breast cancer patients. Breast Cancer Res Treat 2009;117:297-303.
25. Nam BH, Kim SY, Han HS et al. Breast cancer subtypes and survival in patients with brain metastases. Breast Cancer Res 2008;10:R20.
26. Eichler AF, Kuter I, Ryan P et al. Survival in patients with brain metastases from breast cancer: The importance of HER-2 status. Cancer 2008;112: 2359-2367.
27. Dawood S, Broglio K, Esteva FJ et al. Defining prognosis for women with breast cancer and CNS metastases by HER2 status. Ann Oncol 2008; 19:1242-1248.
28. Park IH, Ro J, Lee KS et al. Trastuzumab treatment beyond brain progression in HER2-positive metastatic breast cancer. Ann Oncol 2009;20: 56-62.
29. Church DN, Modgil R, Guglani S et al. Extended survival in women with brain metastases from HER2 overexpressing breast cancer. Am J Clin Oncol 2008;31:250-254.
30. Metro G, Sperduti I, RussilloMet al. Clinical utility of continuing trastuzumab beyond brain progression in HER-2 positive metastatic breast cancer. The Oncologist 2007;12:1467-1469.
31. Duchnowska R, Jassem J, Thorat M et al. Gene expression analysis for prediction of early brain metastasis in HER2-positive breast cancer patients. Presented at the American Society of Clinical Oncology Annual Meeting, Chicago, IL, May 30 to June 3, 2008.
32. Shi Y, Huang W, Tan Y et al. A novel proximity assay for the detection of proteins and protein complexes: Quantitation of HER1 and HER2 total protein expression and homodimerization in formalin-fixed, paraffin-embedded cell lines and breast cancer tissue. Diagn Mol Pathol 2009;18:11-21.
33. Lipton A, Köstler WJ, Leitzel K et al. Quantitative HER2 protein levels predict outcome in fluorescence in situ hybridization-positive patients with metastatic breast cancer treated with trastuzumab. Cancer 2010;116:5168-5178.
34. Toi M, Sperinde J, HuangWet al. Differential survival following trastuzumab treatment based on quantitative HER2 expression and HER2 homodimers in a clinic-based cohort of patients with metastatic breast cancer. BMC Cancer 2010;10:56.
35. Larson JS, Goodman LJ, Tan Y et al. Analytical validation of a highly quantitative, sensitive, accurate, and reproducible assay (HERmark) for the measurement of HER2 total protein and HER2 homodimers in FFPE breast cancer tumor specimens. Patholog Res Int 2010;2010:814176.
36. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999;94:496-509.
37. Lear-Kaul KC, Yoon HR, Kleinschmidt-De-Masters BK et al. HER-2/neu status in breast cancer metastases to the central nervous system. Arch Pathol Lab Med 2003;127:1451-1457.
38. Hoefnagel LD, van de Vijver MJ, van Slooten HJ et al. Receptor conversion in distant breast cancer metastases. Breast Cancer Res 2010;12:R75.
39. Paget S. The distribution of secondary growths in cancer of the breast. Lancet 1889;133: 571-573.
40. Palmieri D, Bronder JL, Herring JM et al. Her-2 overexpression increases the metastatic outgrowth of breast cancer cells in the brain. Cancer Res 2007;67:4190-4198.
41. Da Silva L, Simpson PT, Smart CE et al. HER3 and downstream pathways are involved in colonization of brain metastases from breast cancer. Breast Cancer Res 2010;12:R46.
42. Lockman PR, Mittapalli RK, Taskar KS et al. Heterogeneous blood-tumor barrier permeability determines drug efficacy in experimental brain metastases of breast cancer. Clin Cancer Res 2010;16: 5664-5678.
43. Gril B, Palmieri D, Bronder JL et al. Effect of lapatinib on the outgrowth of metastatic breast cancer cells to the brain. J Natl Cancer Inst 2008;100: 1092-1103.
44. Lin NU, Carey LA, Liu MC et al. Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 2008;26: 1993-1999.
45. Cameron D, Casey M, PressMet al. A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: Updated efficacy and biomarker analyses. Breast Cancer Res Treat 2008;112: 533-543.
46. Gril B, Palmieri D, Qian Y et al. Pazopanib reveals a role for tumor cell B-Raf in the prevention of HER2+ breast cancer brain metastasis. Clin Cancer Res 2011;17:142-153.